Database release
This release covers the 41 pull requests merged between 2026-05-08 and 2026-10-29, and is a formal launch of a 2.0.0 state of moalmanac-db. It adds 60 indications: 9 from FDA, 22 from EMA, 14 from Health Canada (HC), and 15 from the Health Service Executive (HSE). Over the same period, the relational database in referenced/ was rebuilt to align more closely with GA4GH VA-Spec, VRS, and Cat-VRS, and the database content is now licensed under CC BY 4.0.
Database content updates¶
Added entries¶
- (FDA) ER-positive, ESR1 activating variants, and HER2-negative and therapeutic response sensitivity to vepdegestrant for patients with advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Vepdegestrant is a new therapy in the database.
- (FDA) HER2-low or HER2-ultralow and Hormone receptor positive and therapeutic response sensitivity to trastuzumab deruxtecan as monotherapy for patients with unresectable or metastatic breast cancer that has progressed on one or more endocrine therapies in the metastatic setting.
- (FDA) HER2-negative, Hormone receptor positive, and PIK3CA oncogenic variants and therapeutic response sensitivity to palbociclib in combination with fulvestrant and inavolisib for patients with endocrine-resistant, locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy.
- (FDA) HER2-positive and therapeutic response sensitivity to trastuzumab deruxtecan followed by a taxane, trastuzumab, and pertuzumab for the neoadjuvant treatment of patients with Stage II or III breast cancer. The statement was derived with paclitaxel as the taxane, per the supporting clinical trial (DESTINY-Breast11, NCT05113251).
- (FDA) HER2-positive and therapeutic response sensitivity to trastuzumab deruxtecan for the adjuvant treatment of patients with breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.
- (FDA) HER2-positive and Hormone receptor positive and therapeutic response sensitivity to palbociclib in combination with endocrine therapy and trastuzumab, with or without pertuzumab, for patients with locally advanced or metastatic breast cancer following induction treatment. Statements were derived for anastrozole, exemestane, fulvestrant, and letrozole as endocrine therapies, per the agents used as endocrine therapy in the supporting clinical trial (PATINA, NCT02947685).
- (FDA) NRG1 fusions and therapeutic response sensitivity to zenocutuzumab for patients with advanced unresectable or metastatic cholangiocarcinoma with disease progression on or after prior systemic therapy.
- (FDA) PD-L1 (CPS >= 10) and Triple-negative and therapeutic response sensitivity to sacituzumab govitecan in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for patients with unresectable locally advanced or metastatic triple-negative breast cancer in the first-line setting.
- (FDA) PTEN-deficient and therapeutic response sensitivity to capivasertib in combination with abiraterone and prednisone for patients with metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer. The package insert notes that mAPMN/S prostate cancer was previously referred to as metastatic hormone-sensitive prostate cancer.
- (EMA) ABL1 p.T315I and BCR::ABL1 and therapeutic response sensitivity to asciminib for patients with Philadelphia chromosome positive chronic phase chronic myeloid leukaemia who are resistant to, intolerant to, or ineligible for ponatinib.
- (EMA) ABL1 p.T315I and BCR::ABL1 and therapeutic response sensitivity to ponatinib for pediatric patients 6 years and older with chronic phase chronic myeloid leukaemia who are resistant or intolerant to dasatinib or nilotinib, or who have the T315I variant.
- (EMA) BCR::ABL1 and therapeutic response sensitivity to asciminib for patients with Philadelphia chromosome positive chronic phase chronic myeloid leukaemia. This replaces
ind:ema:scemblix:0and drops its requirement of two or more prior tyrosine kinase inhibitors. - (EMA) BCR::ABL1 and therapeutic response sensitivity to ponatinib in combination with cytarabine, dexamethasone, methotrexate, prednisone, and vincristine for patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia.
- (EMA) BRAF fusions, BRAF rearrangements, or BRAF V600 and therapeutic response sensitivity to tovorafenib for patients 6 months and older with pediatric low-grade glioma who have progressed after one or more prior systemic therapies.
- (EMA) BRAF V600 and therapeutic response sensitivity to dabrafenib, as monotherapy or in combination with trametinib, for patients 12 years and older with unresectable or metastatic melanoma. This replaces
ind:ema:tafinlar:0, following the extension to adolescents. - (EMA) BRAF V600 and therapeutic response sensitivity to dabrafenib in combination with trametinib for the adjuvant treatment of patients 12 years and older with Stage III melanoma following complete resection. This replaces
ind:ema:tafinlar:1. - (EMA) BRAF V600 and therapeutic response sensitivity to trametinib, as monotherapy or in combination with dabrafenib, for patients 12 years and older with unresectable or metastatic melanoma. This replaces
ind:ema:mekinist:0, following the 2026-04-30 extension to adolescents. - (EMA) BRAF V600E and therapeutic response sensitivity to cetuximab in combination with encorafenib for patients with metastatic colorectal cancer who have received prior systemic therapy.
- (EMA) BRAF V600E and therapeutic response sensitivity to cetuximab in combination with encorafenib and FOLFOX for the first-line treatment of patients with metastatic colorectal cancer.
- (EMA) BRAF V600E and therapeutic response sensitivity to dabrafenib in combination with trametinib for patients with locally advanced or metastatic differentiated thyroid cancer that is refractory to or not eligible for radioactive iodine and has progressed during or after prior systemic therapy.
- (EMA) BRAF V600E and therapeutic response sensitivity to encorafenib in combination with cetuximab and FOLFOX for the first-line treatment of patients with metastatic colorectal cancer.
- (EMA) BRAF V600E and therapeutic response sensitivity to trametinib in combination with dabrafenib for patients with locally advanced or metastatic differentiated thyroid cancer that is refractory to or not eligible for radioactive iodine and has progressed during or after prior systemic therapy.
- (EMA) BRCA1/2 germline or somatic variants and therapeutic response sensitivity to niraparib and abiraterone acetate in combination with androgen deprivation therapy and prednisone or prednisolone for patients with metastatic hormone-sensitive prostate cancer.
- (EMA) CD22-positive and therapeutic response sensitivity to inotuzumab ozogamicin for pediatric patients 1 year and older with relapsed or refractory B cell precursor acute lymphoblastic leukaemia. A second statement covers Philadelphia chromosome positive disease.
- (EMA) CD30-positive and therapeutic response sensitivity to brentuximab vedotin in combination with cyclophosphamide, dacarbazine, dexamethasone, doxorubicin, and etoposide (BrECADD) for patients with previously untreated Stage IIB with risk factors, Stage III, or Stage IV Hodgkin lymphoma.
- (EMA) EGFR exon 19 deletions or EGFR p.L858R and therapeutic response sensitivity to aumolertinib for the first-line treatment of patients with advanced non-small cell lung cancer. Aumolertinib is a new therapy in the database.
- (EMA) EGFR p.T790M and therapeutic response sensitivity to aumolertinib for patients with advanced non-small cell lung cancer.
- (EMA) ER-positive, ESR1 activating variants, and HER2-negative and therapeutic response sensitivity to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for patients with locally advanced or metastatic breast cancer without disease progression during first-line endocrine therapy with a CDK4/6 inhibitor. Camizestrant, from Etcamah (camizestrant), is a new therapy in the database.
- (EMA) HER2-positive (IHC 3+) and therapeutic response sensitivity to trastuzumab deruxtecan as monotherapy for patients with unresectable or metastatic solid tumours who have received prior treatment and have no satisfactory treatment options.
- (EMA) PD-L1 (CPS >= 1) and therapeutic response sensitivity to pembrolizumab in combination with paclitaxel, with or without bevacizumab, for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received one or two prior systemic treatment regimens.
- (EMA) Triple-negative and therapeutic response sensitivity to sacituzumab govitecan as monotherapy for patients with locally advanced or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy.
- (HC) BCR::ABL1 and therapeutic response sensitivity to dasatinib for patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.
- (HC) BCR::ABL1 and therapeutic response sensitivity to dasatinib for patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
- (HC) BCR::ABL1 and therapeutic response sensitivity to dasatinib for patients with Philadelphia chromosome positive chronic, accelerated, or blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib.
- (HC) BCR::ABL1 and therapeutic response sensitivity to nilotinib for patients with chronic or accelerated phase Philadelphia chromosome positive chronic myeloid leukemia resistant to or intolerant of at least one prior therapy including imatinib.
- (HC) BCR::ABL1 and therapeutic response sensitivity to nilotinib for patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.
- (HC) BCR::ABL1 and therapeutic response sensitivity to nilotinib for pediatric patients 2 years and older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.
- (HC) BCR::ABL1 and therapeutic response sensitivity to nilotinib for pediatric patients 2 years and older with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase with resistance or intolerance to prior therapy including imatinib.
- (HC) BRAF V600E and therapeutic response sensitivity to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer.
- (HC) HER2-negative and Hormone receptor positive and therapeutic response sensitivity to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of patients with stage II to III early breast cancer at high risk of recurrence. Statements were derived for anastrozole and letrozole, each with goserelin.
- (HC) HER2-negative, Hormone receptor positive, and PIK3CA oncogenic variants and therapeutic response sensitivity to alpelisib in combination with fulvestrant for postmenopausal women and men with advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
- (HC) HER2-positive (IHC 3+) and therapeutic response sensitivity to trastuzumab deruxtecan as monotherapy for patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.
- (HC) Homologous recombination repair gene alterations and therapeutic response sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer. Statements were derived for oncogenic and pathogenic variants in ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, and RAD51C.
- (HC) PD-L1 (CPS >= 1) and therapeutic response sensitivity to pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer.
- (HC) Wild-type ALK and Wild-type EGFR and therapeutic response sensitivity to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable Stage II to IIIB non-small cell lung cancer, followed by adjuvant nivolumab.
- (HSE) BCR::ABL1 or CD20-positive and therapeutic response sensitivity to the UKALL14 protocol for induction of remission in newly diagnosed, previously untreated patients aged 25 to 65 years with acute lymphoblastic leukaemia. Statements were derived for daunorubicin, dexamethasone, methotrexate, and vincristine, adding imatinib for BCR::ABL1 disease, rituximab for CD20-positive disease, and both for disease with both biomarkers.
- (HSE) CCND1 overexpression or t(11;14) and therapeutic response sensitivity to ibrutinib as a single agent for patients with relapsed or refractory mantle cell lymphoma.
- (HSE) CD20-positive and therapeutic response sensitivity to obinutuzumab in combination with bendamustine for patients with follicular lymphoma who did not respond to, or progressed during or up to 6 months after, rituximab or a rituximab-containing regimen. Obinutuzumab is a new therapy in the database.
- (HSE) CD20-positive and therapeutic response sensitivity to obinutuzumab in combination with bendamustine for patients with previously untreated advanced follicular lymphoma.
- (HSE) CD20-positive and therapeutic response sensitivity to obinutuzumab in combination with CHOP chemotherapy for patients with previously untreated advanced follicular lymphoma.
- (HSE) CD20-positive and therapeutic response sensitivity to obinutuzumab in combination with CVP chemotherapy for patients with previously untreated advanced follicular lymphoma.
- (HSE) FLT3-ITD and therapeutic response sensitivity to quizartinib as monotherapy for the maintenance treatment of patients with acute myeloid leukaemia in complete response after induction and consolidation chemotherapy.
- (HSE) FLT3-ITD and therapeutic response sensitivity to quizartinib in combination with cytarabine consolidation chemotherapy for patients with newly diagnosed acute myeloid leukaemia.
- (HSE) FLT3-ITD and therapeutic response sensitivity to quizartinib in combination with standard cytarabine and idarubicin induction chemotherapy for patients with newly diagnosed acute myeloid leukaemia.
- (HSE) HER2-negative and PD-L1 (CPS >= 5) and therapeutic response sensitivity to nivolumab in combination with capecitabine and oxaliplatin (XELOX) for the first-line treatment of patients with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
- (HSE) HER2-negative and PD-L1 (CPS >= 5) and therapeutic response sensitivity to nivolumab in combination with fluorouracil and oxaliplatin (FOLFOX-6) for the first-line treatment of patients with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
- (HSE) Mismatch repair deficiency and Microsatellite instability-high and therapeutic response sensitivity to dostarlimab in combination with carboplatin and paclitaxel for patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
- (HSE) PD-L1 (tumour cell expression >= 1%) and therapeutic response sensitivity to nivolumab as monotherapy for the adjuvant treatment of patients with muscle invasive urothelial carcinoma at high risk of recurrence after radical resection who are unsuitable for adjuvant platinum-based chemotherapy.
- (HSE) PD-L1 (TAP >= 5%) and therapeutic response sensitivity to tislelizumab in combination with capecitabine and oxaliplatin for the first-line treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma.
- (HSE) PD-L1 (TAP >= 5%) and therapeutic response sensitivity to tislelizumab in combination with fluorouracil and oxaliplatin for the first-line treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma.
Revised entries¶
- (FDA) HER2-negative, Hormone receptor positive, and PIK3CA, AKT1, or PTEN alterations and therapeutic response sensitivity to capivasertib in combination with fulvestrant for patients with locally advanced or metastatic breast cancer. Test wording was updated from "FDA-approved test" to "FDA-authorized test" to match the new label, and a typo in the raw therapeutics was corrected.
- (FDA) Four Enhertu indications (
ind:fda:enhertu:1,:2,:4, and:5) were updated to match the 2026-05-15 label: "FDA-approved test" became "FDA-authorized test", and "as monotherapy" was added to the tumour-agnostic indication. - (FDA) NPM1 p.W288Cfs*12 and therapeutic response sensitivity to revumenib for patients 1 year and older with relapsed or refractory acute myeloid leukemia who have no satisfactory alternative treatment options. Statements for acute lymphoblastic leukemia, Burkitt lymphoma, and acute leukemias of ambiguous lineage, which were added in error, were removed, and a stray period was removed from the statement description.
- (FDA) PD-L1 (CPS >= 10) and therapeutic response sensitivity to pembrolizumab for patients with locally advanced or metastatic esophageal or gastroesophageal junction carcinoma of squamous cell histology after one or more prior lines of systemic therapy. The two existing statements, for esophageal adenocarcinoma and adenocarcinoma of the gastroesophageal junction, were deprecated and replaced with one statement for esophageal squamous cell carcinoma.
- (EMA) BRAF V600 and therapeutic response sensitivity to trametinib in combination with dabrafenib for the adjuvant treatment of patients 12 years and older with Stage III melanoma following complete resection. Extended from adults to adults and adolescents aged 12 years and older.
- (EMA) Four Retsevmo (selpercatinib) indications (
ind:ema:retsevmo:0through:3) were updated to the 2026-06-04 label. The thyroid and tumour-agnostic indications now cover patients 2 years and older, and the conditional marketing authorisation was converted to a full one. - (EMA) Five indications were marked as superseded and now record when that happened:
ind:ema:mekinist:0,ind:ema:tafinlar:0, andind:ema:tafinlar:1on 2026-04-30;ind:ema:scemblix:0on 2025-11-17; andind:ema:jemperli:0on 2025-01-15, by a broader approval with no biomarker requirement, which is not in the database. - (EMA and HSE) Statements for Philadelphia chromosome positive acute lymphoblastic leukaemia had used propositions with BCR::ABL1 absent. They now use BCR::ABL1 present, for
ind:ema:glivec:2,ind:ema:glivec:3,ind:ema:sprycel:1,ind:ema:sprycel:3,ind:ema:iclusig:1,ind:hse:00302:b,ind:ema:blincyto:0,ind:ema:besponsa:0, andind:hse:00537:a. - (EMA and HSE) Statements for esophageal squamous cell carcinoma were added to
ind:ema:keytruda:9andind:hse:00739:a. Both indications cover both histologies, but only esophageal adenocarcinoma was represented before. - (EMA and HSE) Indication descriptions were updated to state how the product information defines HER2-positive, and whether a separate ERBB2 amplification statement applies was revised to match:
ind:ema:enhertu:0,ind:ema:kadcyla:0,:1, and:10,ind:ema:herceptin:3,ind:hse:00217:a,ind:hse:00272:athrough:d, andind:hse:00285:athrough:d. - (EMA and HSE) Indication descriptions were updated to name the therapies given in combination for
ind:ema:opdivo:6,ind:ema:vanflyta:0,ind:hse:00525:a, andind:hse:00844:a. The statement description forind:ema:enhertu:4had described a different Enhertu indication and was corrected. - (EMA) European Commission dates were corrected for 15 indications that had carried the product's first authorisation date. They now carry the date of the variation that added them, for Faslodex, Glivec, Herceptin, Keytruda, Kisqali, MabThera, Tafinlar, Tagrisso, and Tyverb indications.
- (HC) BCR::ABL1 and therapeutic response sensitivity to asciminib for patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase who are newly diagnosed or who have received one prior tyrosine kinase inhibitor. Updated from patients previously treated with two or more tyrosine kinase inhibitors.
- (HC) HER2-negative, Hormone receptor positive, and PIK3CA amplification and therapeutic response sensitivity to capivasertib in combination with fulvestrant for females with locally advanced or metastatic breast cancer following progression on at least one endocrine-based regimen. Two statements were added for PR-positive and ER-positive/PR-positive disease with PIK3CA amplification, matching those for this indication's other biomarkers.
- (HC) PD-L1 (CPS >= 1) and therapeutic response sensitivity to pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma, as neoadjuvant monotherapy continued as adjuvant treatment with radiotherapy with or without cisplatin. This ID previously held the cervical cancer indication, which is now
ind:hc:keytruda:12. - (HSE) CD30-positive and therapeutic response sensitivity to brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for patients with relapsed or refractory Hodgkin lymphoma. The statement incorrectly listed HER2-negative as a required biomarker alongside CD30-positive.
- (HSE) PD-L1 (CPS >= 1) and therapeutic response sensitivity to pembrolizumab for the maintenance treatment of patients with persistent, recurrent, or metastatic cervical cancer who have completed the induction chemotherapy component of treatment. Updated to the current regimen, which moved this indication from second-line monotherapy to maintenance.
ind:hse:00558:jwas revised in the same way. - (HSE) Three indications that had been withdrawn because of errors on the HSE side were reinstated:
ind:hse:00570:b(lorlatinib for ALK fusion non-small cell lung cancer), andind:hse:00414:aand:b(palbociclib for HER2-negative, hormone receptor positive breast cancer). - (HSE) Reimbursement dates or reimbursement schemes were corrected for 33 indications. Each now follows the reimbursement effective date stated in its NCCP regimen or, where the regimen states none, the month listed in the HSE Cancer Drugs Approved for Reimbursement list.
- Proposition-level corrections changed the statements of several indications at once:
- Eight propositions for FLT3 alterations and gilteritinib referenced acute lymphoid leukemia instead of acute myeloid leukemia.
- Propositions for "Chronic Myelogenous Leukemia" were consolidated into "Chronic Myeloid Leukemia, BCR-ABL1+", and the resulting duplicate statements were deprecated.
- The disease of 21 propositions for "gastric or gastroesophageal junction adenocarcinoma" indications changed from Adenocarcinoma of the Gastroesophageal Junction to Esophagogastric Adenocarcinoma.
prop:vtxr:964now includes pembrolizumab in its therapy group.- One EMA Keytruda statement (
ind:ema:keytruda:9) was deprecated so that only regimens tested in the supporting trial (KEYNOTE-590) remain active. - Editorial corrections were made across about 40 indications. Unicode characters (≥, α, ï, curly quotes, en dashes) were replaced with ASCII. Typos were fixed ("lapatinib", "refractory", "lorlatinib", "pembrolizumab"). Supporting-trial details were added to several statement descriptions, and the raw cancer type of
ind:ema:mekinist:3was corrected.
Removed entries¶
- (HSE) 18 HSE indications were marked Withdrawn in the 2026-08-02 HSE update, and their statements were deprecated:
ind:hse:00200:a,00200:b,00215:e,00215:g,00225:c,00253:a,00253:b,00254:a,00254:b,00254:c,00328:a,00335:a,00335:b,00361:a,00361:b,00397:a,00430:a, and00506:a. The records were kept, not deleted.
Feature updates¶
Repository and schema changes in this release:
- Concept identifiers. Integer primary and foreign keys were replaced with structured, self-describing strings, for example
stmt:fda:tevimbra:1:0andprop:vtxr:0(Issue 51). Dereferenced per-concept files now use_instead of:in their file names, so they work on Windows. - Indications as Information Entities. Indications now follow VA-Spec's Information Entity model: each one has its own contributions,
reportedIndocuments, and asuperseded_bylist. Dereferenced indications carry their statement description as an extension. - Status. Every document, indication, and statement now has a
status. Statement status is propagated from the indication: Approved or Accelerated gives Active, Superseded gives Superseded, and Withdrawn gives Deprecated. Statements now holdstatusandindicationas extensions, per the VA-Spec Statement model. - Biomarkers. Biomarkers were refactored to align with VRS and Cat-VRS. A new biomarker criteria table pairs each biomarker with a
presentflag. Biomarkers now dereference to Defining Allele, Copy Change, Function, Feature Context, Adjacency, and Defining Location constraints. New tables hold VRS alleles, sequence references, and sequence locations for curated genes' MANE Select transcripts, protein products, exons, chromosome arms, and whole chromosomes. Cat-VRS does not yet support sets of categorical variants, sosubjectVariantis a placeholder and the biomarkers are carried as an extension. - JSON schemas. Schemas were added for both the referenced and dereferenced records and are checked by the test suite. Extensions were removed from
referenced/records, except biomarkers, to fit the API's SQLite databases. Gene fusions and translocations are now biomarker types of their own. - Codings. The NCI Thesaurus is now the primary coding for diseases, with mappings to OncoTree (updated to the 2025-10-03 release). SNOMED mappings were removed. Scripts were added to download the NCI Thesaurus, OncoTree, and RefSeq.
- Documents. Each FDA label now has a dated document record alongside the evergreen one, and each FDA indication links to both its current label and the label that first approved it.
identification_numberwas renamed toregulatory_identifier, and FDA values are now prefixed application numbers such asNDA207103.companyis now nullable. - Licensing and documentation. The database content is now licensed under CC BY 4.0. The scripts in
utils/andtests/remain under GPL v2. A contributing guide, a Development section in the README, and a revised pull request template were added. The environment now uses Python 3.14.
Implementation details¶
- Evergreen FDA documents and label URLs were updated for Bizengri (2026-05-08), Enhertu (2026-05-15), Ibrance (2026-06-24), Trodelvy (2026-06-24), and Truqap (the label revised in September 2026), and documents were added for Veppanu.
doc:hse:00414is Active again and points to the corrected 2026-08-11 regimen. HPRA documents for Arimidex, Aromasin, and Femara gained regulatory identifiers. - Documents grew from 415 to 1,605 and URLs from 694 to 1,890, mostly from the dated FDA label history. Contributions grew from 57 to 558 as approval, supersession, and curation events were recorded on each indication.
- Indications grew from 842 to 902, and statements from 1,895 to 2,072. Of the statements, 55 are now Deprecated and 6 are Superseded.
- A total of 80 propositions (
prop:vtxr:546andprop:vtxr:915throughprop:vtxr:995) and 27 therapy groups (txgrp:198throughtxgrp:224) were added, and 15 duplicate propositions were removed. Several of the new propositions have no statements yet and were added for upcoming UK NICE curation, for example fruquintinib for KRAS and NRAS wild-type colorectal cancer, tebentafusp for HLA-A*02:01 uveal melanoma, and rucaparib and niraparib for ovarian cancers with or without HRD or BRCA1/2 variants. - Seven therapies were added: aumolertinib, camizestrant, dexamethasone, fruquintinib, obinutuzumab, tebentafusp, and vepdegestrant.
- Six biomarkers were added: CCND1 overexpression, HLA-A*02:01, PD-L1 < 1% IC, PD-L1 > 0%, PTEN-deficient, and t(11;14). The AKT1 and PIK3CA "somatic variants" biomarkers were renamed to "oncogenic variants". EZH2 p.A862G and H3-3A p.K27M are now named EZH2 p.A682G and H3-3A p.K28M.
- Diseases were renamed or consolidated as part of the move to NCI Thesaurus codings. For example, "Acute Lymphoid Leukemia" is now "Acute Lymphoblastic Leukemia", "Acute Promyelocytic Leukemia with PML::RARA" is now "Acute Promyelocytic Leukemia", and "Low-Grade Glioma, NOS" is now "Low-Grade Glioma". Anaplastic large cell lymphoma is no longer marked as a solid tumor. Mantle Cell Lymphoma and Differentiated Thyroid Gland Carcinoma were added.
- Eight new HC indications do not have derived statements yet:
ind:hc:piqray:1,ind:hc:sprycel:3through:5, andind:hc:tasigna:4through:7. - Agent last-updated dates are FDA 2026-06-24, EMA 2026-08-02, HSE 2026-08-02, and HC 2026-05-22.
referenced/about.jsonwas last updated on 2026-10-28, with release2.0.0.